Catalyst Wire Dossier Catalyst Wire Dossier

DFF332

· Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for DFF332, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies [Phase 1]

See pricing